

# Elise AasebÃ,

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5716966/publications.pdf>

Version: 2024-02-01

29  
papers

569  
citations

623734

14  
h-index

642732

23  
g-index

30  
all docs

30  
docs citations

30  
times ranked

721  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Blood Contamination and the Rostro-Caudal Gradient on the Human Cerebrospinal Fluid Proteome. <i>PLoS ONE</i> , 2014, 9, e90429.	2.5	54
2	Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients. <i>Biological Procedures Online</i> , 2016, 18, 13.	2.9	48
3	Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. <i>Signal Transduction and Targeted Therapy</i> , 2019, 4, 20.	17.1	46
4	Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows. <i>Journal of Proteomics</i> , 2016, 145, 214-225.	2.4	35
5	The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles. <i>Cancers</i> , 2020, 12, 1466.	3.7	33
6	Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia. <i>Cancers</i> , 2020, 12, 709.	3.7	33
7	Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. <i>Proteomics</i> , 2014, 14, 1971-1976.	2.2	32
8	Therapeutic targeting of leukemic stem cells in acute myeloid leukemia – the biological background for possible strategies. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1053-1065.	5.0	32
9	Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients. <i>Current Pharmaceutical Biotechnology</i> , 2015, 17, 52-70.	1.6	27
10	High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype. <i>Journal of Clinical Medicine</i> , 2019, 8, 970.	2.4	26
11	Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity. <i>Cells</i> , 2020, 9, 1155.	4.1	25
12	Selecting Sample Preparation Workflows for Mass Spectrometry-Based Proteomic and Phosphoproteomic Analysis of Patient Samples with Acute Myeloid Leukemia. <i>Proteomes</i> , 2016, 4, 24.	3.5	19
13	The Capacity of Long-Term in Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome. <i>Cancers</i> , 2019, 11, 73.	3.7	18
14	The Extracellular Bone Marrow Microenvironment – A Proteomic Comparison of Constitutive Protein Release by In Vitro Cultured Osteoblasts and Mesenchymal Stem Cells. <i>Cancers</i> , 2021, 13, 62.	3.7	16
15	Proteomic Comparison of Bone Marrow Derived Osteoblasts and Mesenchymal Stem Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5665.	4.1	15
16	Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 639-653.	3.4	14
17	Biological characteristics of aging in human acute myeloid leukemia cells: the possible importance of aldehyde dehydrogenase, the cytoskeleton and altered transcriptional regulation. <i>Aging</i> , 2020, 12, 24734-24777.	3.1	13
18	Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. <i>Journal of Proteomics</i> , 2018, 173, 32-41.	2.4	11

#	ARTICLE	IF	CITATIONS
19	Proteomic Profiling of Primary Human Acute Myeloid Leukemia Cells Does Not Reflect Their Constitutive Release of Soluble Mediators. <i>Proteomes</i> , 2019, 7, 1.	3.5	11
20	The Constitutive Extracellular Protein Release by Acute Myeloid Leukemia Cells – A Proteomic Study of Patient Heterogeneity and Its Modulation by Mesenchymal Stromal Cells. <i>Cancers</i> , 2021, 13, 1509.	3.7	11
21	Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity. <i>Journal of Personalized Medicine</i> , 2021, 11, 779.	2.5	11
22	Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 13-24.	2.2	9
23	Rethinking the role of osteopontin in human acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 1494-1497.	1.3	6
24	Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid. <i>Cancers</i> , 2021, 13, 2143.	3.7	6
25	An Overview on G Protein-coupled Receptor-induced Signal Transduction in Acute Myeloid Leukemia. <i>Current Medicinal Chemistry</i> , 2019, 26, 5293-5316.	2.4	5
26	Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 74.	2.5	4
27	How should quality of life assessment be integrated in the evaluation of patients with acute myeloid leukemia?. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 373-387.	0.6	3
28	Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome. <i>International Journal of Molecular Sciences</i> , 2018, 19, 296.	4.1	3
29	Proteomic Characterization of Spontaneous Stress-Induced In Vitro Apoptosis of Human Acute Myeloid Leukemia Cells; Focus on Patient Heterogeneity and Endoplasmic Reticulum Stress. <i>Hemato</i> , 2021, 2, 607-627.	0.6	3